---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-001587"
form_type: "8-K"
ticker: "ALDX"
cik: "0001341235"
company_name: "Aldeyra Therapeutics, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:31:56.246817+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aldeyra Q3 net loss $14.6M; reproxalap NDA on track for Q4 2022; cash $185M

## Summary
- Net loss of $14.6M ($0.25 per share) for Q3 2022 vs $15.8M ($0.27) for Q3 2021.
- Cash, cash equivalents, and marketable securities of $185.3M as of Sep 30, 2022; expected to fund operations through end of 2023.
- NDA submission for reproxalap in dry eye disease remains on schedule for Q4 2022; package includes data from five adequate and well-controlled trials.
- Pre-NDA meeting with FDA scheduled in Q4 2022 to discuss ADX-2191 for primary vitreoretinal lymphoma; NDA possible by end of 2022.
- Top-line results from Phase 2 trial of ADX-629 in acute alcoholic hepatitis expected by end of 2022; ADX-2191 retinitis pigmentosa trial results expected H1 2023.

## SEC filing metadata
- accession: 0001157523-22-001587
- form_type: 8-K
- ticker: ALDX
- cik: 0001341235
- company_name: Aldeyra Therapeutics, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1341235/000115752322001587/0001157523-22-001587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1341235/000115752322001587/a52965769.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-001587
- JSON: https://secwatch.observer/filing/0001157523-22-001587.json
- Plain text: https://secwatch.observer/filing/0001157523-22-001587.txt

## Key facts
- Earnings Releases
  Aldeyra Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $14.6 million, EPS $0.25 per share.
  - Period: the quarter ended September 30, 2022
  - Net income: Net loss for the three months ended September 30, 2022 was $14.6 million
  - EPS: $0.25 per share
  - Result: reported results
  source text: Net loss for the three months ended September 30, 2022 was $14.6 million, or $0.25 per share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1341235/000115752322001587/0001157523-22-001587-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.